Brepocitinib Overview & RVT-3101 Update
VTAMA (tapinarof)
VTAMA! Psoriasis | Dermavant
(tapinarof) cream 1%
VTAMA/Atopic Dermatitis | Dermavant
(tapinarof) cream 1%
RVT-3101 Ulcerative Colitis | New Vant
RVT-3101 Crohn's Diseases | New Vant
BREPOCITINIB Dermatomyositis | Priovant
BREPOCITINIB Systemic Lupus Erythematosus | Priovant
Modality
Preclinical
Phase 1
Topical
Topical
Biologic
Biologic
Small Molecule
Small Molecule
BREPOCITINIB Other Indications | Priovant
Small Molecule
BATOCLIMAB Myasthenia Gravis | Immunovant
Y
BATOCLIMAB Thyroid Eye Disease | Immunovant
Biologic
Biologic
BATOCLIMAB Chronic Inflammatory Demyelinating Polyneuropathy | Immunovant
Biologic
др
BATOCLIMAB Graves' Disease | Immunovant
Biologic
BATOCLIMAB Warm Autoimmune Hemolytic Anemia | Immunovant
Biologic
Y
IMVT-1402 Numerous Indications | Immunovant
Biologic
n
NAMILUMAB Sarcoidosis | Kinevant
Biologic
RVT-2001 Transfusion-Dependent Anemia in Patients with Lower-Risk MDS | Hemavant
roivant
Pipeline reflects both ongoing clinical trials and expected upcoming trials. VTAMA has only received FDA approval for psoriasis, not atopic dermatitis.
Small Molecule
Phase 2
Phase 3
Approved
A
A
A
A
A
Represents registrational or potentially
registrational trials
15
For investor audiences onlyView entire presentation